Abbvie Contract MFG

Modern drug development needs more than just innovation—it needs efficiency, precision, and scalability. That’s where proprietary hot melt extrusion shines. As an advanced formulation technology, HME services help pharmaceutical companies overcome major challenges like poor solubility, low bioavailability, and inconsistent drug release. With AbbVie’s proprietary hot melt extrusion systems, you gain access to powerful, proven tools for enhancing drug performance. Let’s break down how HME works—and why AbbVie leads the way in proprietary solutions. What Is Proprietary Hot Melt Extrusion? Hot melt extrusion (HME) is a process that transforms drug and polymer mixtures into solid dispersions. It improves how drugs dissolve in the body, making therapies more effective. AbbVie’s proprietary hot melt extrusion takes this one step further. It combines specialized polymers, patented equipment, and unique processing conditions to enhance performance, reproducibility, and scale. The resu...

Hot Melt Extrusion (HME) is an innovative and versatile technology that has revolutionized the pharmaceutical industry. This process involves melting and shaping materials to create solid dispersions, enhancing the bioavailability of poorly soluble drugs, and enabling controlled release formulations. Proprietary HME services offer a competitive edge in drug development by providing tailored solutions that address specific pharmaceutical challenges. Enhancing Bioavailability One of the significant advantages of proprietary HME is its ability to enhance the bioavailability of poorly soluble drugs. Many new drug candidates suffer from low solubility, which limits their effectiveness. HME improves this by dispersing the active pharmaceutical ingredient (API) uniformly within a polymer matrix, creating an amorphous solid dispersion. This increases the surface area of the API, facilitating faster dissolution and improved absorption in the body. Companies offering proprietary HME service...